CLARK IAN T 4

What Happened

• Ian T. Clark, a director of BioMarin Pharmaceutical Inc. (BMRN), received an award of 7,490 restricted stock units (RSUs) on June 2, 2026. The grant is reported as an award/ grant (transaction code A) and shows $0.00 as the acquisition price because RSUs are not purchased.

Key Details

• Transaction date: June 2, 2026; Form 4 filed: June 4, 2026 (appears timely under Section 16 reporting rules).
• Amount: 7,490 RSUs granted; reported acquisition price: $0.00 (price not applicable for RSU awards).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: F1 — “Restricted stock units granted on June 2, 2026. Price not applicable.”
• No indication of a 10b5‑1 plan, cashless sale, tax withholding, or late filing in the supplied data.

Context

• RSUs are a form of equity compensation that convert to common shares upon vesting; this grant is an award rather than a market purchase or sale, so it should not be read as an immediate buy or sell signal.
• Such grants are common for directors and executives as compensation or retention tools; the economic value will depend on BioMarin’s future stock price and the RSUs’ vesting terms (not detailed in the filing).